TORONTO, May 16, 2024
/PRNewswire/ -- Visionary Holdings Inc. (the "Company")
(NASDAQ: GV), a private education provider with technology of
artificial intelligence and life science on the cutting edge, with
subsidiaries in Canada and market
partners in China, today announced
the Company has cooperated with Canada's B. Braun Biochip Technology Group to
establish Visionary Biotechnology Group Co., Ltd. in Toronto. Both economic value and social value
will have an important impact. Visionary Group has a global impact
in the field of biotechnology. Important value for short, medium
and long term investors.
Visionary Group has world-class biochip technology products to
fill the vast market gap in Canada. B. Braun was founded in March 2011 at UBC University in Vancouver, Canada by Victor C.M. Leung, an academician of the Royal
Canadian Academy of Sciences and the Academy of Engineering, and
other Canadian academicians and American academician professors. B.
Braun has invested nearly 150 million US
dollars. After more than 10 years of focusing on the
development of biochips, it has cooperated with the United States, and famous Canadian medical
institutions have cooperated to develop a variety of products for
medical bed testing, drug research and development, animal
quarantine and cold chain transportation, including medical chips,
animal chips, cold chain chips and agricultural chips. Currently,
the products have Complete clinical testing, process technology
verification and small-scale production.
The ability to realize applications in clinical testing, process
validation and small-scale production demonstrates B. Braun's
advantages and progress in this technical field. In addition, B.
Braun cooperated with Ruikun Technology Group to build a factory in
Nantong, China, with a total
investment of US$300 million. This
investment will not only help fill China's technological gaps in this field, but
is also expected to bring up to 30 million
US dollars in the next five years. The output value of more
than 100 million US dollars will have
an important impact on the economic value and social value of the
B. Braun Group.
Visionary Group has cooperated with China's Zhejiang Ruikun Technology Group to
build a factory in Nantong, China
with a total investment of US$300
million to fill the gap in China's vast market. It is planned to be put
into production in March 2025, with
an output value of more than 3 billion US
dollars in the next five years, creating huge economic and
social value for the Vision Group.
Innovative biochip technology demonstrates the company's
world-class achievements in the field of biotechnology. Through
long-term dedicated research and development of biochip technology
and cooperation with famous medical institutions in North America, the company has successfully
developed a variety of products that are used in many fields such
as medical treatment, drug research and development, animal
quarantine, and cold chain transportation.
Vision Biotechnology Group Co., Ltd.'s innovative biochip
technology demonstrates the company's world-class achievements in
the field of biotechnology. Through long-term dedicated research
and development of biochip technology, the company has successfully
developed a variety of products that are used in medical treatment,
drug research and development, animal quarantine and cold chain
transportation due to cooperation with medical institutions of the
famous Canadian B. Braun Biochip Technology Group in North America. and many other fields.
Medical chips, animal chips, cold chain chips and agricultural
chip products can be used in clinical testing, process verification
and small-scale production, showing that Vision Biotechnology Group
Co., Ltd.'s B. Braun Biochip Technology is the Top 1 market in this
technology field. Advantage. In addition, B. Braun Biochip
Technology has cooperated with Ruikun Technology Group to build a
factory in Nantong, China, with a
total investment of US$300 million.
This investment will not only help fill China's technology gap in this field, but is
also expected to bring about With an output value of more than
3 billion US dollars, it will have an
important impact on both the economic value and social value of
Vision Biotechnology Group Co., Ltd.
- Medical chip, animal chip, cold chain chip and agricultural
chip technology innovation: The cooperation between Vision Group
and B. Braun's biochip technology company represents the
combination of global high-end manufacturing and biotechnology,
which brings innovative solutions to key industries such as medical
care. plan.
- Leading the biochip market: Top 1 medical chips, animal
chips, cold chain chips and agricultural chips fill the gaps in the
Canadian and Chinese markets. B. Braun holds a leading position in
the global biochip market.
- Cooperation and expansion: Vision Group's cooperation with
internationally renowned institutions and the expansion of its
global production base show its high growth potential and
influence.
- Global social contribution: Providing
high-precision biochip products helps improve the health and
welfare of humans and animals around the world.
- High economic value: The expected output value of more than
3 billion US dollars in the next five
years shows its huge market potential and economic benefits.
Vision Group and B. Braun Group jointly established Vision
Biotechnology Group Co., Ltd., which is moving towards becoming an
important force in the global biochip industry and making
significant contributions to global medical/health/new agricultural
innovation technologies in all aspects of business and society.
Biochips Market Size And Industry
Analysis
The global Biochips Market Size was valued at $12,005 million in 2021 and is projected to reach
$25,568 million in 2028. The market
is likely to grow with a high CAGR of 11.3% during the forecast
period. The report presents comprehensive projections on the growth
factors, opportunities, and restraining factors. It also covers the
geographical market along with comprehensive competitive landscape
analysis.
Biochip Market: Overview
Biochip is a biosecurity miniaturized medical device which helps
in tracking accurate information. Additionally, it is massively
used in molecular biology. These chips are capable of undergoing
thousands of biological reactions in less time.
COVID-19 Impact:
The outbreak of the Covid-19 pandemic is likely to positively
impact the growth of the global biochip market. Its growing
applications align with the innovation of the Covid-19 vaccines and
drugs, which in turn also contributes to the growth of the market
during the pandemic. Its ability to find the gene sequences along
with an array of biochemical constituents is likely to play an
imperative role in fueling the adoption rate of biochips,
particularly among the academic research space. Among the Covid-19
pandemic, the biochip companies are looking forward to capitalizing
on the opportunities in the current market landscape. The growing
initiatives by the government and big private firms to develop
novel solutions to fast track the development of the Covid-19
vaccines and drugs.
Biochip Market: Growth Drivers
Growing usage of biochips in diverse areas will drive the growth
of the global market.
Biochip technologies are widely deployed across different areas,
including microbiology, DNA analysis, clinical pathology,
pharmacology, proctology, and biochemistry, among others. The
ongoing research activities will fuel the usage of biochip
technologies, particularly in the healthcare industry, which in
turn will further expand the usage of biochips in the mainstream
market in the forthcoming years. Biochip technology is also being
used in sequence engineering, which is likely to augment the growth
of the global biochip market and improve the performance &
scalability of biochips solutions. Biochip manufacturers are
emphasizing innovating distinct aspects of their miniature
laboratory that can function properly with living organisms.
Biochips have also emerged as a crucial aspect to revolutionize
DNA sequencing technology. Furthermore, it is likely to pave the
way for advanced gene sequencing solutions. The combination of gene
sequencing technology and biochip will address a number of
biological tissues in the rare cell, single-cell, and red molecule
analysis. However, biochip technology is growing continuously, and
its throughput capacity is likely to expand the scope to diverse
applications ranging from population-centric clinical studies to
the detection of rare bacteria. Manufacturers are investing heavily
in biochips for single-cell analysis. Investments are also likely
to contribute towards the improvement of biochips and their
versatile functions to enhance performance graphs
exponentially.
Market dynamics
Miniaturization of laboratory facilities can save time and cost,
broad product portfolio offered by manufacturers and wide range of
biochip applications are driving the growth of the biowafer market.
Manufacturers provide technologically advanced products to minimize
time and costs and enhance research outcomes. For example,
Micralyne, Inc. launched Silicon MicraFluidics technology in
February 2018, a series of
standardized microfluidic process technologies that enable rapid
design and deployment of microfluidic-based products. Research and
development to expand the scope of applications, and the advantages
offered by biochip technology over traditional laboratories in
terms of time, cost, and ease of use are expected to drive market
growth.
About Visionary Holdings Inc.
Visionary Holdings Inc. headquartered in Toronto, Canada, a private education provider
with technology of artificial intelligence and life science on the
cutting edge, with subsidiaries in Canada and market partners in China. The Company aims to provide access to
secondary, college, undergraduate and graduate and vocational
education to students in Canada
through technological innovation so that more people can learn,
grow and succeed to their full potential. As a fully integrated
provider of educational programs and services in Canada, the Company has been serving and will
continue to serve both Canadian and international students. For
more information, visit the Company's website at
https://ir.visiongroupca.com/.
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements. These forward-looking
statements involve known and unknown risks and uncertainties and
are based on the Company's current expectations and projections
about future events that the Company believes may affect its
financial condition, results of operations, business strategy and
financial needs. Investors can identify these forward-looking
statements by words or phrases such as "believes," "expects,"
"anticipates," "estimates," "intends," "would," "continue,"
"should," "may," or similar expressions. The Company undertakes no
obligation to update or revise publicly any forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's registration statement and in its other filings with the
SEC.
For more information, please contact:
Visionary Holdings Inc.
Investor Relations Department
Email: ir@farvision.ca
View original
content:https://www.prnewswire.com/news-releases/visionary-has-world-class-biochip-technology-products-302147260.html
SOURCE Visionary Holdings Inc.